BIOMARIN PHARMACEUTICAL INC.

Lobbying for BIOMARIN PHARMACEUTICAL INC.

Filing 1st Quarter - Report

Reporting period

1st Quarter 2026

Jan 1 - Mar 31 · Posted Apr 20, 2026

Expenses

$530,000.00

What this organization spent lobbying with its own staff. Reported using A: the three LDA methods count different costs, so an expenses figure is not comparable across filers that used different ones.

Client based in

California

Official filing document

Government bodies contacted 5

Commerce, Dept of (DOC)
Food & Drug Administration (FDA)
Health & Human Services, Dept of (HHS)
HOUSE OF REPRESENTATIVES
SENATE

The chambers, agencies and offices the filer named. It does not say who inside them was contacted, or when.

Lobbying activity 3

Tariff (miscellaneous tariff bills)

GENERAL DISCUSSIONS REGARDING SECTION 232 INVESTIGATION ON BIOPHARMACEUTICALS

Health Issues

GENERAL DISCUSSIONS REGARDING GENETIC TESTING AND NEWBORN SCREENING GENERAL DISCUSSIONS REGARDING ORPHAN DRUGS GENERAL DISCUSSIONS RELATED TO THE PRIORITY REVIEW VOUCHER PROGRAM EXTENSION GENERAL DISCUSSIONS RELATED TO TARIFFS ON PHARMACEUTICALS GENERAL DISCUSSIONS RELATED TO METABOLIC DISORDER PUBLIC HEALTH CAMPAIGN GENERAL DISCUSSIONS RELATED TO RARE DISEASE DRUG DEVELOPMENT

Medicare/Medicaid

GENERAL DISCUSSIONS RELATED TO MOST-FAVORED-NATION (MFN) FOREIGN REFERENCE PRICING GENERAL DISCUSSIONS REGARDING MEDICAID PRIOR AUTHORIZATION

Source: federal Lobbying Disclosure Act filing, reproduced as filed. Bills are parsed from the activity descriptions.